Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00865605 · ClinicalTrials.gov registry record · Phase 1
Pivotal Bioequivalence Study of Topically Delivered Halobetasol Propionate Ointment in Normal Skin in Healthy Adult Subjects
A Phase 1 study, sponsored by Actavis.
- Completed
- Registry status
- Phase 1
- Development phase
- 71
- Enrollment target
NCT00865605 is a Phase 1 study that has completed, run by Actavis. The registered enrollment target is 71 participants.
The verdict
NCT00865605, a Phase 1 study, has completed, sponsored by Actavis.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 71 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the vasoconstriction response profile and bioequivalence between one innovator lot of Ultravate® 0.05% ointment and one test/generic lot of Halobetasol propionate 0.05% ointment (Alpharma USPD, Inc.).
Interventions
- DRUG Ultravate® 0.05% ointment, single exposure
- DRUG Halobetasol Propionate 0.05% Ointment, single exposure
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 71 participants |
| Start Date | 2003-12 |
| Est. Completion | 2004-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00865605
The ClinicalTrials.gov registry entry for NCT00865605 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 71 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Actavis, which has 79 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ultravate® 0.05% ointment, single exposure is the first listed.
NCT00865605 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00865605 about?
NCT00865605 is a clinical study titled "Pivotal Bioequivalence Study of Topically Delivered Halobetasol Propionate Ointment in Normal Skin in Healthy Adult Subjects". The purpose of this study is to compare the vasoconstriction response profile and bioequivalence between one innovator lot of Ultravate® 0.05% ointment and one test/generic lot of Halobetasol propionate 0.05% ointment (Alpharma USPD, Inc.).
What is the current status of trial NCT00865605?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 71 participants. The study started on 2003-12. Estimated completion is 2004-07.
What interventions are being tested in trial NCT00865605?
The interventions under investigation include: Ultravate® 0.05% ointment, single exposure (DRUG), Halobetasol Propionate 0.05% Ointment, single exposure (DRUG).
Who is sponsoring clinical trial NCT00865605?
This trial is sponsored by Actavis, which has 79 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.